Revance Therapeutics, Inc. Stock News

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Revance Therapeutics, Inc. (NasdaqGM: RVNC) to Crown Laboratories, Inc. Under the terms of the proposed transaction, shareholders of Revance will receive $3.10 in cash for each share of Revance that they own. KSF ...

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Revance (NASDAQ: RVNC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crown. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the revised transaction, Reva...

Board of Directors of Revance Recommend Stockholders Tender their Shares JOHNSON CITY, Tenn. , Dec. 12, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that it has commenced a cash tender offer to acquire all outstanding shares of common stock of Revance Therapeutics, Inc., ("Revance") (Nasdaq: RVNC) a...

Anti-wrinkle injection maker Revance Therapeutics has agreed to be bought for $3.10 per share by privately held Crown Laboratories, instead of $6.66 per share agreed previously, the two companies said on Monday.

JOHNSON CITY, Tenn. and NASHVILLE, Tenn.

JOHNSON CITY & NASHVILLE, Tenn.--(BUSINESS WIRE)--Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement.

The hyaluronic acid market is poised for substantial growth over the coming years driven by its diverse applications, increasing consumer demand for beauty and wellness products, and advancements in manufacturing technologies. The hyaluronic acid market is poised for substantial growth over the coming years driven by its diverse applications, increasing consumer demand for beauty and wellness p...

PHILADELPHIA, PA / ACCESSWIRE / November 8, 2024 / Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Revance Therapeutics Inc. ("Revance" or the "Company") (NASDAQ:RVNC).